Pien Tze Huang'S Third Quarterly Report Releases Steady Growth, Profit Growth Slows Down

Recently, many listed nutrition and health care products enterprises have disclosed their third quarter reports in 2024. These reports not only reflect their business conditions in the past quarter, but also reveal the competition pattern and development trend of the whole nutrition and health care product market. Among them, as a pioneer in the field of traditional Chinese medicine and health care products, Pien Tze Huang's third quarter report is particularly eye-catching.

On October 19, Pienz Huang released his report for the third quarter of 2024. The report shows that in the first three quarters of 2024, Pienz Huang achieved a revenue of 8.450 billion yuan, up 11.19% year on year; The net profit attributable to the parent company reached 2.687 billion yuan, up 11.73% year on year. Although both revenue and net profit achieved double growth, it is worth noting that the growth rate decreased by 5.43 percentage points compared with the same period last year, showing a slowing trend of profit growth.

In terms of gross profit rate, the gross profit rate of Pienze Huang in the first three quarters totaled 45.54%, a decrease of 2.98 percentage points compared with the same period last year. Among them, the gross profit margin of main business drugs for liver diseases and drugs for cardiovascular and cerebrovascular diseases decreased by 7.40% and 26.03% respectively, which affected the overall profitability of the company to a certain extent. Nevertheless, the revenue of the Pienze Huang series products still maintained a steady growth, which was mainly due to the company's continuous efforts in brand building and market promotion.

It is worth mentioning that this is the first time that the net profit of Pienz Huang has exceeded 2.5 billion yuan, marking the further consolidation of the company's position in the field of traditional Chinese medicine and health care products. However, the slowdown of net profit growth has also attracted the attention of the market. Analysts pointed out that this was mainly due to the high price of natural bezoar, musk and other core Chinese medicinal materials, which led to the rise of the company's production costs, and thus affected the profit level.

Faced with the rising pressure of raw material prices, Pienz Huang did not wait to be killed. The company has actively taken a series of measures to address this challenge. On the one hand, Pienz Huang strengthened communication and cooperation with suppliers, and tried to reduce procurement costs; On the other hand, the company has also increased the research and development of alternative raw materials to reduce production costs without affecting product quality.

In addition, Pienze Huang also pays attention to brand building and market promotion. The company has continuously improved its brand reputation and reputation by increasing advertising efforts and carrying out online and offline marketing activities. At the same time, the company also actively develops new markets and channels to expand sales scale and market share.

Looking forward to the future, Pienze Huang will continue to improve product quality and service level. At the same time, the company will continue to increase R&D investment and market expansion efforts to promote the sustainable and healthy development of the enterprise.